Voluntary announcement strategic cooperation agreement with shanghai shenqi medical technology co., ltd. to advance the commercialisation of the bioheart bioabsorbable rapamycin-eluting coronary stent system
Filed with HKEX · Stock code 2185 · · 3 pages · English
Shanghai Bio-heart Biological Technology Co., Ltd. 上海百心安生物技术股份有限公司 (A joint stock company incorporated in the People’s Republic of China with limited liability) (Stock Code: 2185) VOLUNTARY ANNOUNCEMENT STRATEGIC COOPERATION AGREEMENT WITH SHANGHAI SHENQI MEDICAL TECHNOLOGY CO., LTD. TO ADVANCE THE COMMERCIALISATION OF THE BIOHEART® BIOABSORBABLE RAPAMYCIN-ELUTING CORONARY STENT SYSTEM THE BIOHEAR
Shanghai Bio-Heart Biological Technology Co., Ltd. on 6ix
Earlier from Shanghai Bio-Heart Biological Technology
Later from Shanghai Bio-Heart Biological Technology
- Announcement pursuant to rule 13.51B(2) of the listing rules
- Notice of 2026 first extraordinary general meeting
- Proposed appointment of independent non-executive director; and (2) notice of 2026 first extraordinary general meeting
- Proxy form for use at the 2026 first extraordinary general meeting to be held on October 9, 2026
- 2026 Interim report
Follow Shanghai Bio-Heart Biological Technology into a list and get an email when it puts out news.
Follow Shanghai Bio-Heart Biological Technology